Pfizer claims Metsera breached their merger agreement, adding that a tie-up of the biotech with GLP-1 drug giant Novo Nordisk ...

With federal PBM reform stalled, states like California are stepping up with laws like SB 41 to boost transparency and lower drug costs.

Bidding to buy metabolic medicines biotech Metsera in September came down to two pharmaceutical giants, with Novo Nordisk’s higher offer losing out to Pfizer’s $4.9 billion price in part due to ...

From left to right: Moderator Dennis Dailey, editor at mHealth Times; Dave Chokshi, primary care doctor at Bellevue Hospital and chair of the Common Health Coalition; Pete November, CEO of Ochsner ...

At the HLTH 2025 conference, healthcare executives shared how their companies perceive the shifting healthcare landscape and how their health tech companies fit into it. Wolters Kluwer Health Director ...

The expiration of ACA tax credits could drive up premiums across marketplace and commercial insurance plans, a Cigna executive warned.

Bayer’s Lynkuet, approved for treating moderate-to-severe vasomotor symptoms of menopause, targets two receptors key to ...

The Rural Health Transformation Program (RHTP) is more than a funding bill: It’s a $50 billion lifeline for rural hospitals on the brink of collapse, and time is running out to be positioned for ...

For decades, the patient referral process has been plagued by inefficiency and fragmentation. Patient data remains scattered across systems, forcing staff to spend excessive time manually compiling ...

Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal.